Format

Send to

Choose Destination
Genome Med. 2017 Dec 14;9(1):110. doi: 10.1186/s13073-017-0504-3.

Narrowing the spectrum: the new frontier of precision antimicrobials.

Author information

1
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA.
2
Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO, 63110, USA.
3
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.
4
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA. hultgren@wustl.edu.
5
Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO, 63110, USA. hultgren@wustl.edu.

Abstract

Antibiotics have become the standard of care for bacterial infections. However, rising rates of antibiotic-resistant infections are outpacing the development of new antimicrobials. Broad-spectrum antibiotics also harm beneficial microbial communities inhabiting humans. To combat antibiotic resistance and protect these communities, new precision antimicrobials must be engineered to target specific pathogens.

PMID:
29241446
PMCID:
PMC5729598
DOI:
10.1186/s13073-017-0504-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center